Comparing Folfoxiri Plus Bevacizumab With Doublet Chemotherapy Plus Anti-Egfr Antibody: A Systemic Review And Network Meta-Analysis

Jianwei Zhang,Jianxia Li,Xiaoyu Xie,Yue Cai,Zehua Wu,Huabin Hu,Miaomiao Ding,Yanhong Deng

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 1|浏览15

暂无评分

摘要

97Background: FOLFOXIRI plus bevacizumab (Triplet+Bev) improved survival benefit when comparing with doublet chemotherapy plus Bev (doublet+Bev) as initial treatment in metastatic colorectal cancer...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要